Hung Yi-Ping, Yang Yi-Ping, Wang Hsien-Chi, Liao Jiunn-Wang, Hsu Wei-Li, Chang Chao-Chin, Chang Shih-Chieh
Department of Veterinary Medicine, College of Veterinary Medicine, National Chung Hsing University, 250 Kuo-Kuang Road, Taichung 40227, Taiwan.
Veterinary Medical Teaching Hospital, College of Veterinary Medicine, National Chung Hsing University, 250 Kuo-Kuang Road, Taichung 40227, Taiwan.
Vet J. 2014 Oct;202(1):76-82. doi: 10.1016/j.tvjl.2014.06.006. Epub 2014 Jun 10.
Feline lymphocytic-plasmacytic gingivitis/stomatitis (LPGS) or caudal stomatitis is an inflammatory disease that causes painfully erosive lesions and proliferations of the oral mucosa. The disease is difficult to cure and can affect cats at an early age, resulting in lifetime therapy. In this study, a new treatment using a combination of bovine lactoferrin (bLf) oral spray and oral piroxicam was investigated using a randomized double-blinded clinical trial in 13 cats with caudal stomatitis. Oral lesion grading and scoring of clinical signs were conducted during and after the trial to assess treatment outcome. Oral mucosal biopsies were used to evaluate histological changes during and after treatment. Clinical signs were significantly improved in 77% of the cats. In a 4-week study, clinical signs were considerably ameliorated by oral piroxicam during the first 2 weeks. In a 12-week study, the combined bLf oral spray and piroxicam, when compared with piroxicam alone, exhibited an enhanced effect that reduced the severity of the oral lesions (P = 0.059), while also significantly improving clinical signs (P <0.05), quality of life (P <0.05), and weight gain (P <0.05). The remission of oral inflammation was closely correlated with the decreased number of macrophages (OR = 4.719, P < 0.05). There was no detectable influence on liver or kidney function during a 12-week assessment. It was concluded that combining oral bLf spray and piroxicam was safe and might be used to decrease the clinical signs of caudal stomatitis in cats.
猫淋巴细胞性浆细胞性龈炎/口炎（LPGS）或尾部口炎是一种炎症性疾病，可导致口腔黏膜出现疼痛性糜烂性病变和增生。该疾病难以治愈，可在猫幼年时发病，需要终身治疗。在本研究中，采用随机双盲临床试验，对13只患有尾部口炎的猫使用牛乳铁蛋白（bLf）口腔喷雾剂和口服吡罗昔康联合治疗的新方法进行了研究。在试验期间和试验后对口腔病变进行分级并对临床症状进行评分，以评估治疗效果。通过口腔黏膜活检评估治疗期间和治疗后的组织学变化。77%的猫临床症状有显著改善。在一项为期4周的研究中，口服吡罗昔康在前2周可使临床症状明显改善。在一项为期12周的研究中，与单独使用吡罗昔康相比，bLf口腔喷雾剂和吡罗昔康联合使用增强了疗效，减轻了口腔病变的严重程度（P = 0.059），同时还显著改善了临床症状（P <0.05）、生活质量（P <0.05）和体重增加（P <0.05）。口腔炎症的缓解与巨噬细胞数量减少密切相关（OR = 4.719，P <0.05）。在为期12周的评估中，未发现对肝脏或肾脏功能有可检测到的影响。研究得出结论，口服bLf喷雾剂和吡罗昔康联合使用是安全的，可用于减轻猫尾部口炎的临床症状。
